GRAIL (NASDAQ:GRAL) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of GRAIL (NASDAQ:GRAL) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other research firms have also recently commented on GRAL. Mizuho lifted their price target on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. The Goldman Sachs Group initiated coverage on GRAIL in a research report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price objective for the company. TD Cowen reiterated a “buy” rating on shares of GRAIL in a research note on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Friday, July 17th. Finally, Wolfe Research started coverage on GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $67.78.

GRAIL Price Performance

Shares of GRAL stock opened at $80.34 on Friday. The stock has a market cap of $3.59 billion, a P/E ratio of -8.24 and a beta of 3.25. The company has a fifty day moving average price of $72.78 and a two-hundred day moving average price of $62.59. GRAIL has a one year low of $33.61 and a one year high of $118.84.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. The company had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. As a group, equities research analysts anticipate that GRAIL will post -10.41 EPS for the current fiscal year.

Insider Activity at GRAIL

In other news, CFO Aaron Freidin sold 7,900 shares of GRAIL stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $85.01, for a total value of $671,579.00. Following the completion of the sale, the chief financial officer directly owned 253,083 shares in the company, valued at approximately $21,514,585.83. The trade was a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joshua Ofman sold 5,000 shares of GRAIL stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $85.02, for a total value of $425,100.00. Following the completion of the transaction, the chief executive officer directly owned 397,271 shares of the company’s stock, valued at $33,775,980.42. This represents a 1.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.83% of the stock is currently owned by company insiders.

Institutional Trading of GRAIL

Large investors have recently bought and sold shares of the business. Fifth Third Bancorp boosted its position in GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after buying an additional 472 shares in the last quarter. Comerica Bank raised its position in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in GRAIL in the fourth quarter valued at approximately $28,000. Geneos Wealth Management Inc. raised its holdings in GRAIL by 160.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after purchasing an additional 360 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new position in shares of GRAIL in the 4th quarter worth approximately $31,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.